Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec;25(12):1467-1482.
doi: 10.1007/s11912-023-01469-3. Epub 2023 Nov 8.

Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan

Niraj Neupane  1 , Sangharsha Thapa  2 , Abhinav Bhattarai  3   4 , Kriti Ahuja  5 , Ilana Schlam  6   7 , Abhenil Mittal  8 , Sara M Tolaney  9   10 , Paolo Tarantino  11   12   13
Affiliations
Review

Opportunities and Challenges for a Histology-Agnostic Utilization of Trastuzumab Deruxtecan

Niraj Neupane et al. Curr Oncol Rep. 2023 Dec.

Abstract

Purpose of review: This review delves into the prospects and challenges offered by a potential pan-histological utilization of trastuzumab deruxtecan (T-DXd) in patients with advanced solid tumors.

Recent findings: The HER2-targeted antibody-drug conjugate (ADC) T-DXd has shown broad activity across cancer types, with current indications for patients with biomarker-selected breast, gastric, and non-small-cell lung cancer and relevant activity observed in multiple histology-specific trials. Moreover, two recently reported phase 2 trials (DESTINY-Pantumor02 and HERALD) have supported the potential for a pan-cancer utilization of this ADC in patients with advanced cancers expressing HER2 or with HER2 amplifications. By improving the delivery of cytotoxic chemotherapy, ADCs have allowed for meaningful clinical advantages in broad populations of cancer patients, often leading to survival advantages over conventional chemotherapy. Notably, the broad spectrum of activity of certain ADCs has led to the hypothesis of a histology-agnostic utilization based on detecting specific biomarkers, similar to what is already established for certain targeted treatments and immunotherapy. To date, T-DXd has shown the broadest activity across cancer types, with current approvals in breast, gastric, and lung cancer, and relevant antitumor activity observed in a multiplicity of additional cancer types. The optimization of the drug dose, identification of predictive biomarkers, and clarification of mechanisms of resistance will be critical steps in view of a pan-histological expansion in the use of T-DXd.

Keywords: Antibody-drug conjugate; Biomarkers; HER2; Histology-agnostic; T-DXd; Trastuzumab deruxtecan.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–8. - PubMed
    1. Stewart JSW, Cohen EEW, Licitra L, Van Herpen CML, Khorprasert C, Soulieres D, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. JCO. 2009;27(11):1864–71.
    1. Seligson ND, Knepper TC, Ragg S, Walko CM. Developing drugs for tissue-agnostic indications: a paradigm shift in leveraging cancer biology for precision medicine. Clin Pharmacol Ther. 2021;109(2):334–42. - PubMed
    1. Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11–9. - PubMed
    1. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10. https://doi.org/10.1200/JCO.19.02105 .

LinkOut - more resources